Company

Research programs

  • Firibastat, hypertension as monotherapy - whose synopsis of a pivotal Phase III study will be submitted to the relevant health authorities.
  • QGC011, hypertension in combination - pre-clinical phase
  • QGC006, optimized treatment of hypertension as monotherapy
  • Firibstat, for the prevention and treatment of heart failure

Quantum Genomics

Quantum Genomics is a biopharmaceutical company specializing in the development of a new drug class for unmet medical needs in cardiovascular disease, including high blood pressure and heart failure.

Quantum Genomics research programs are based on the brain inhibition mechanism of Aminopeptidase A (BAPAI – Brain Aminopeptidase A Inhibitors), a truly innovative triple-action therapeutic platform developed by the academic research laboratories of the Collège de France and INSERM.

Quantum Genomics is the only biopharmaceutical company specializing in the development of a new drug class based on the central action mechanism of Aminopeptidase A inhibition.

Quantum Genomics is the only biopharmaceutical company specializing in the development of a new drug class based on the central action mechanism of Aminopeptidase A inhibition.